The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28242276 |
45 |
Synthesis of dihydroimidazole tethered imidazolinethiones and their activity as novel antagonists of the nuclear retinoic acid receptor-related orphan receptors (RORs). |
Torrey Pines Institute For Molecular Studies |
| 26819660 |
82 |
SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor. |
Central Pharmaceutical Research Institute |
| 26277758 |
48 |
Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent ROR¿t inverse agonists. |
Fudan University |
| 26048789 |
143 |
Discovery of novel pyrazole-containing benzamides as potent ROR¿ inverse agonists. |
Biogen |
| 24502334 |
123 |
Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-¿ (ROR¿ or RORc). |
Genentech |
| 24900774 |
40 |
Discovery of Tertiary Amine and Indole Derivatives as Potent ROR?t Inverse Agonists. |
Glaxosmithkline |
| 24388993 |
76 |
Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent ROR¿t inhibitors. |
Glaxosmithkline |
| 32334911 |
22 |
Substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t (ROR?t) agonists. |
Bristol Myers Squibb |
| 32334912 |
130 |
Discovery and optimization of new oxadiazole substituted thiazole ROR?t inverse agonists through a bioisosteric amide replacement approach. |
Phenex Pharmaceuticals |
| 32551004 |
32 |
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR?t Inverse Agonist. |
Bristol Myers Squibb |
| 31272795 |
154 |
Discovery and pharmacological evaluation of indole derivatives as potent and selective ROR?t inverse agonist for multiple autoimmune conditions. |
Advinus Therapeutics |
| 30743096 |
36 |
Discovery of N-indanyl benzamides as potent ROR?t inverse agonists. |
Fudan University |
| 31638797 |
193 |
Rationally Designed, Conformationally Constrained Inverse Agonists of ROR?t-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy. |
Bristol-Myers Squibb |
| 31223457 |
71 |
Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2. |
Astrazeneca |
| 30130103 |
90 |
Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist. |
Karo Pharma |
| 30301676 |
91 |
Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (ROR?t) inhibitor, S18-000003. |
Shionogi |
| 29456799 |
30 |
From ROR?t Agonist to Two Types of ROR?t Inverse Agonists. |
Fudan University |
| 1652050 |
19 |
Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. |
Seattle Veterans Affairs Medical Center |
| 19125156 |
4 |
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. |
University of Texas Southwestern Medical Center |
Search and Browse
